Cas:1256355-75-5 [4-[(2,4-dichlorophenyl)methoxy]phenyl]boronic acid manufacturer & supplier

Chemical Name:[4-[(2,4-dichlorophenyl)methoxy]phenyl]boronic acid

CAS.NO:1256355-75-5

Synonyms:(4-((2,4-Dichlorobenzyl)oxy)phenyl)boronic acid;4-(2,4-DICHLOROPHENYLMETHOXY)PHENYLBORONIC ACID

Molecular Formula:C₁₃H₁₁BCl₂O₃

Molecular Weight:296.94200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:49.69000

Exact Mass:296.01800

LogP:2.25220

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (4-((2,4-Dichlorobenzyl)oxy)phenyl)boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(2,4-DICHLOROPHENYLMETHOXY)PHENYLBORONIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-((2,4-Dichlorobenzyl)oxy)phenyl)boronic acid Use and application,4-(2,4-DICHLOROPHENYLMETHOXY)PHENYLBORONIC ACID technical grade,usp/ep/jp grade.

Related News: A CDMO must have bolt-on capabilities with efficient chemistry which translates into adding new capabilities that the specific molecule development may require quickly. trimethyl(piperidin-1-ylmethyl)silane manufacturers During Covid-19, the company has helped fill a void in meeting API demand for medicines used to treat patients with the virus. In April of last year, Wavelength expanded its production of API for three generic drugs— sedative midazolam, muscle relaxant cisatracurium, and paralytic rocuronium — to help keep up with hospital demand. 4,4-dimethyl-2-trimethylsilylpentanoic acid suppliers Improved gene mining techniques have permitted previously uncharacterized gene clusters to be discovered, while advances in heterologous expression and production have allowed the encoded enzymes to rapidly be scaled up and evaluated as tools for organic synthesis. 3-trimethylsilylpropyl carbamate vendor & factory In 2021, the combo has raked in $818 million in the first half of the year alone for Novartis, a number that is already up 11% from last year. Comparatively, Roche reported $218 million in sales of Zelboraf in 2016, and revenue was not reported in its most recent mid-year update.,EMA’s human medicines committee (CHMP) has endorsed findings of a review which concluded that there is no evidence Zynteglo causes a blood cancer known as acute myeloid leukaemia (AML).